Harpoon Therapeutics has treated the first patient in a Phase l clinical trial to investigate the safety, tolerability and pharmacokinetics of HPN424 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

The multicentre, multinational, open-label, ascending-dose trial aims to enrol around 40 metastatic prostate cancer patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In the first stage of the trial, patients will receive a once-weekly dose of HPN424 via intravenous (IV) infusion with dose escalation until a therapeutic dose level has been reached.

After completing the dose-escalation phase, Harpoon is expected to further analyse the safety and efficacy of HPN424 in a Phase ll trial by including additional cohorts of patients to administer the recommended dose established in the first phase of the Phase l trial.

“Around 26,000 men in the US are currently estimated to die from prostate cancer after receiving treatment with the available therapies.”

Harpoon Therapeutics president and CEO Jerry McMahon said: “HPN424 is the first Tri-specific T-cell Activating Construct (TriTAC) compound to enter clinical testing and represents a novel class of T-cell therapeutics aiming to achieve superior efficacy in penetrating and killing solid tumours.

“Data is expected in 2019, and should provide the safety assessment, pharmacokinetics and pharmacodynamics to determine the optimal dose and regimen for our additional planned trials in prostate cancer, the third leading cause of cancer deaths for men in the US.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Around 26,000 men in the US are currently estimated to die from prostate cancer after receiving treatment with the available therapies.

HPN424 is an investigation compound designed as a new T-cell therapy that can overcome the loss of human leukocyte antigen (HLA) expression, a common means used by cancer cells to escape T-cell recognition.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact